Julie Rozenblyum
About Julie Rozenblyum
Julie Rozenblyum is the Senior Vice President of Business Development at Bristol Myers Squibb, with over 15 years of experience in investment banking and business development, particularly in the healthcare sector.
Title
Julie Rozenblyum serves as the Senior Vice President of Business Development at Bristol Myers Squibb. She transitioned to this role in 2024 after a distinguished career in investment banking focused on healthcare.
Company
Julie Rozenblyum currently works at Bristol Myers Squibb, a global biopharmaceutical company. In her role as Senior Vice President of Business Development, she is responsible for driving new business opportunities and expanding Bristol Myers Squibb's reach in the biopharmaceutical sector.
Background
Julie Rozenblyum has an extensive background in healthcare investment banking, having spent over 15 years at Morgan Stanley. Her roles ranged from Associate to Managing Director, reflecting her progressive ascent in the industry. Her career at Morgan Stanley was marked by her significant contributions to mergers and acquisitions within the healthcare sector.
Education and Expertise
Julie Rozenblyum holds a Master of Business Administration (MBA) from The University of Chicago Booth School of Business, achieved in 2008. She also earned a Master of Arts (MA) in International Relations and Affairs from Johns Hopkins School of Advanced International Studies (SAIS) in 2001, and a Bachelor of Arts (BA) in International/Global Studies from The Johns Hopkins University in 2000. Her educational background has provided a solid foundation for her career in investment banking and business development.
Achievements
Over her career, Julie Rozenblyum has held several progressively senior roles in investment banking at Morgan Stanley, ultimately becoming the Managing Director of Healthcare Investment Banking. She accumulated extensive experience in mergers and acquisitions within the healthcare sector, showcasing her expertise and strategic acumen. Her successful transition to a top leadership role at Bristol Myers Squibb in 2024 highlights her continued impact on the industry.